Obstructive Pulmonary Disease COPD

COPD is the third and fourth leading cause of disability and death, respectively, in the US, and costs the American economy over 30 billion per year [238]. Among patients with COPD, 20-40% ofthese will suffer from muscle wasting [239]. Loss of muscle mass can adversely impact quality of life, exercise tolerance and survival. 

Like the other conditions discussed above, patients with COPD have a higher prevalence of hypogonadism than their healthier counterparts [240]. Chronic steroid use may exacerbate muscle loss and weakness in this group. Although unproven, treatment of these symptoms with a SARM could offer considerable improvement of quality of life in these patients as well as those who are treated with chronic corticosteroids for rheumatologic or other inflammatory diseases. These are examples of chronic conditions where decades of anabolic therapy may be needed. An anabolic agent that reduces the morbidity and mortality associated with these conditions without unwanted effects would serve a huge unmet need in this patient population. 

---

Chronic obstructive pulmonary disease (COPD) affects over 5% of the adult population, is the fourth leading cause of death worldwide and is the only major cause of mortality that is increasing worldwide. It is an inflammatory disorder of the lungs, caused mainly, but not exclusively, by cigarette smoking. 15-20% of smokers develop COPD. 

Chronic Obstructive Pulmonary Disease. Figure 1 Pharmacotherapy of chronic obstructive pulmonary disease (COPD). 

Other disorders of the lower respiratory tract include emphysema (lung disorder in which the terminal bronchioles or alveoli become enlarged and plugged with mucus) and chronic bronchitis (chronic inflammation and possibly infection of die bronchi). Chronic obstructive pulmonary disease (COPD) is die name given collectively to emphysema and chronic bronchitis because die obstruction to die airflow is present most of the time. Asdima diat is persistent and present for most of die time may also be referred to as COPD. 

A 65-year-old man with a history of osteoarthritis and chronic obstructive pulmonary disease (COPD) comes to your clinic complaining of burning abdominal pain. The pain has worsened over the past 2 weeks it is worse at night and after meals. 

Celik F and Topcu F. 2006. Nutritional risk factors for the development of chronic obstructive pulmonary disease (COPD) in male smokers. Clin Nutr 25(6) 955-961. 

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. The most common conditions comprising COPD are chronic bronchitis and emphysema. 

The symptoms of many chronic diseases, such as rheumatoid arthritis, multiple sclerosis, asthma and chronic obstructive pulmonary disease (COPD) are caused in large part by an excessive and chronic inflammatory response and are therefore potential human diseases for drugs which inhibit the SSAO/VAP-1 activity. Notably, it has been recently shown that patients suffering from either atopic eczema or psoriasis, both chronic inflammatory skin disorders, demonstrate an increase in SSAO/VAP-1 positive vessels in their skin compared to skin from healthy controls [47,48]. 

Aerosolised medicines have been used for centuries to treat respiratory diseases, with inhalation therapy for the airways focused primarily on the treatment of asthma and chronic obstructive pulmonary disease (COPD). The development of new products for delivery to the lungs for these respiratory diseases includes new steroids and beta agonists plus combination products featuring both agents. New classes of anti-asthma medication are also being developed for inhalation with the aim of delivering them directly to the inflamed airways. 

Many disorders benefit from exercise (Pederson Saltin, 2005). These include asthma, cancer, chronic heart failure, coronary artery disease, chronic obstructive pulmonary disease (COPD), depression, type 1 diabetes melUtus, type 2 diabetes melUtus, hypertension, intermittent claudication, osteoarthritis, osteoporosis, rheumatoid arthritis and obesity. 

Tlotropium bromide (54 Spiriva Boehringer-Ingelheim/Pfizer, 2004) has been approved by the US Eood and Drug Administration (EDA) for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). Tiotropium, a derivative of atropine from Atropa belladonna (Solanaceae), is a potent reversible nonselective inhibitor of... 

Until now we have been discussing natural product HDAC inhibitors and their benefits for pathophysiological conditions. However, recent research shows that for treatment of a few diseased conditions, it is beneficial to increase HDAC activity. One such example is chronic obstructive pulmonary disease (COPD). 

Particulate matter air pollution is especially harmful to people with lung disease such as asthma and chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, as well as people with heart disease. Exposure to particulate air pollution can trigger asthma attacks and cause wheezing, coughing, and respiratory irritation in individuals with sensitive airways. It was estimated in one major study that the excess risk of total mortality is 6.2% per each increase in 10pgPM2.s/m and 9.3% for cardiopulmonary mortality. ... 

Chronic obstructive pulmonary disease (COPD)- For long-term, twice daily (morning and evening) administration in the maintenance of bronchoconstriction in patients with COPD including chronic bronchitis and emphysema. 

Chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis For the twice-daily maintenance treatment of airflow obstruction in patients with COPD associated with chronic bronchitis. Fluticasone propionate/salmeterol 250 meg per 50 meg twice daily is the only approved dosage for the treatment of COPD associated with chronic bronchitis. Fligher doses, including fluticasone propionate/salmeterol 500 meg per 50 meg, are not recommended. 

---